AU2016343851B2 - Eflornithine and sulindac, fixed dose combination formulation - Google Patents

Eflornithine and sulindac, fixed dose combination formulation Download PDF

Info

Publication number
AU2016343851B2
AU2016343851B2 AU2016343851A AU2016343851A AU2016343851B2 AU 2016343851 B2 AU2016343851 B2 AU 2016343851B2 AU 2016343851 A AU2016343851 A AU 2016343851A AU 2016343851 A AU2016343851 A AU 2016343851A AU 2016343851 B2 AU2016343851 B2 AU 2016343851B2
Authority
AU
Australia
Prior art keywords
composition
tablet
sulindac
eflomithine
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016343851A
Other languages
English (en)
Other versions
AU2016343851A1 (en
Inventor
Roberto Carlos Bravo Gonzalez
Jean Ducassou
Patrick Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uswm LLC
Original Assignee
Usmw LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usmw LLC filed Critical Usmw LLC
Priority claimed from PCT/US2016/059689 external-priority patent/WO2017075576A1/en
Publication of AU2016343851A1 publication Critical patent/AU2016343851A1/en
Application granted granted Critical
Publication of AU2016343851B2 publication Critical patent/AU2016343851B2/en
Assigned to USMW, LLC reassignment USMW, LLC Request for Assignment Assignors: CANCER PREVENTION PHARMACEUTICALS, INC.
Assigned to USWM, LLC reassignment USWM, LLC Request to Amend Deed and Register Assignors: USMW, LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016343851A 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation Active AU2016343851B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562248810P 2015-10-30 2015-10-30
US62/248,810 2015-10-30
US201662358698P 2016-07-06 2016-07-06
US62/358,698 2016-07-06
EP16306429.8 2016-10-28
EP16306429 2016-10-28
EP16306430 2016-10-28
EP16306430.6 2016-10-28
PCT/US2016/059689 WO2017075576A1 (en) 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation

Publications (2)

Publication Number Publication Date
AU2016343851A1 AU2016343851A1 (en) 2018-05-10
AU2016343851B2 true AU2016343851B2 (en) 2022-04-07

Family

ID=57256487

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016343851A Active AU2016343851B2 (en) 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation

Country Status (14)

Country Link
US (4) US10973790B2 (enExample)
EP (1) EP3368029A1 (enExample)
JP (3) JP2018536707A (enExample)
KR (2) KR20240162560A (enExample)
CN (1) CN108366982A (enExample)
AU (1) AU2016343851B2 (enExample)
BR (1) BR112018008651A2 (enExample)
CA (1) CA3003149C (enExample)
CL (1) CL2018001157A1 (enExample)
CO (1) CO2018005491A2 (enExample)
HK (1) HK1258284A1 (enExample)
IL (1) IL259009A (enExample)
MA (1) MA43114A (enExample)
MX (1) MX390899B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43114A (fr) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals Inc Formulation combinée à dose fixe d'éflornithine et sulindac
MX390145B (es) * 2016-10-06 2025-03-20 Orbus Therapeutics Inc Formulaciones para la administracion de eflornitina
CN114096240A (zh) * 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法
CN119909027B (zh) * 2025-01-21 2025-11-18 福安药业集团宁波天衡制药有限公司 一种稳定的舒林酸片及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309442A (en) * 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
WO1999049859A1 (en) * 1998-03-28 1999-10-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dfmo and sulindac combination in cancer chemoprevention
US20020110590A1 (en) * 1996-11-01 2002-08-15 Ilex Oncology, Inc. Pharmaceutical formulation containing DEMO for the treatment of cancer
US20050059690A1 (en) * 2002-11-29 2005-03-17 Forest Laboratories, Inc. Method of treating acute pain with a unitary dosage form comprising ibuprofen and oxycodone
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
EP2438919A1 (en) * 2006-07-18 2012-04-11 Horizon Pharma USA, Inc. Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US7700568B2 (en) 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
EP1140194A2 (en) 1998-12-23 2001-10-10 G.D. SEARLE & CO. Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
WO2002015895A2 (en) 2000-08-24 2002-02-28 The Regents Of The University Of California Alpha-difluoromethylornithine (dfmo) use in the human prostate
GB0125492D0 (en) 2001-10-24 2001-12-12 Astrazeneca Ab Formulation
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
WO2007012019A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US9072778B2 (en) 2005-12-20 2015-07-07 University Of Hawaii Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
GEP20125672B (en) 2007-07-19 2012-10-25 Takeda Pharmaceuticals Co ) solid composition containing alogliptin and metformin hydrochloride
CA2694389C (en) 2007-08-01 2016-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Treatment of pediatric tumors
WO2009022670A1 (ja) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited 速崩壊性錠剤
WO2009048932A2 (en) 2007-10-09 2009-04-16 Children's Medical Center Corporation Methods to regulate mirna processing by targeting lin-28
WO2009052518A2 (en) * 2007-10-19 2009-04-23 Aspen Benefits Group, Llc Methods and compositions directed to reduction of facial hair hirsutism in females
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
AU2009333510A1 (en) 2008-12-08 2011-06-30 The Procter & Gamble Company Personal care composition in the form of an article having a hydrophobic surface-resident coating
EP2430452B1 (en) * 2009-05-14 2014-06-25 Arizona Board of Regents on Behalf of University of Arizona Carcinoma diagnosis and treatments, based on odc1 genotype
US20120259013A1 (en) 2009-05-20 2012-10-11 Ranbaxy Laboratories Limited Liquid dosage forms of isotretinoin
CN101898978A (zh) 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
JP6083646B2 (ja) 2010-05-14 2017-02-22 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ａｒｉｚｏｎａ 食事性ポリアミン含量に基づく癌予防及び治療法
US8853423B2 (en) * 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
GB2513299A (en) 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
KR102286386B1 (ko) * 2013-10-07 2021-08-05 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 언리미티드 컴퍼니 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
JP2017519770A (ja) 2014-06-18 2017-07-20 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティ オブ アリゾナ Ｏｄｃ１遺伝子型に基づく癌腫の診断および処置
EP3256117A4 (en) 2015-02-12 2018-10-10 The Arizona Board of Regents on behalf of The University of Arizona Methods for treating neuroblastoma
MA43114A (fr) * 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals Inc Formulation combinée à dose fixe d'éflornithine et sulindac
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309442A (en) * 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US20020110590A1 (en) * 1996-11-01 2002-08-15 Ilex Oncology, Inc. Pharmaceutical formulation containing DEMO for the treatment of cancer
WO1999049859A1 (en) * 1998-03-28 1999-10-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dfmo and sulindac combination in cancer chemoprevention
US20050059690A1 (en) * 2002-11-29 2005-03-17 Forest Laboratories, Inc. Method of treating acute pain with a unitary dosage form comprising ibuprofen and oxycodone
EP2438919A1 (en) * 2006-07-18 2012-04-11 Horizon Pharma USA, Inc. Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anonymous, "NCT01245816 on 2015_04_23: ClinicalTrials.gov Archive", (2015-04-23), URL: https://clinicaltrials.gov/archive/NCT01245816/2015_04_23, (2017-01-20) *
Anonymous, "NCT01483144 on 2015_07_28: ClinicalTrials.gov Archive", (2015-07-28), URL: https://clinicaltrials.gov/archive/NCT01483144/2015_07_28, (2017-01-20) *
MEYSKENS F. L. et al., "Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial", CANCER PREVENTION RESEARCH, (2008-04-14), vol. 1, no. 1, pages 32 - 38 *

Also Published As

Publication number Publication date
MX2018005350A (es) 2018-08-14
CN108366982A (zh) 2018-08-03
US20200009098A1 (en) 2020-01-09
KR20180069068A (ko) 2018-06-22
US11925613B2 (en) 2024-03-12
EP3368029A1 (en) 2018-09-05
AU2016343851A1 (en) 2018-05-10
KR20240162560A (ko) 2024-11-15
US10973790B2 (en) 2021-04-13
US12350246B2 (en) 2025-07-08
CO2018005491A2 (es) 2018-06-12
JP7592001B2 (ja) 2024-11-29
CA3003149A1 (en) 2017-05-04
US11529326B2 (en) 2022-12-20
US20240173284A1 (en) 2024-05-30
CL2018001157A1 (es) 2018-09-07
CA3003149C (en) 2023-10-31
BR112018008651A2 (pt) 2018-10-30
MX390899B (es) 2025-03-21
JP2018536707A (ja) 2018-12-13
JP2024102339A (ja) 2024-07-30
JP2022028814A (ja) 2022-02-16
MA43114A (fr) 2018-09-05
US20230172887A1 (en) 2023-06-08
IL259009A (en) 2018-07-31
US20210267926A1 (en) 2021-09-02
HK1258284A1 (zh) 2019-11-08

Similar Documents

Publication Publication Date Title
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
BR112012028035B1 (pt) formulação de liberação imediata
US10207002B2 (en) Sustained release formulation and tablets prepared therefrom
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
CA3104695A1 (en) Formulations of ag10
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
JP2021518422A (ja) レナリドミドを含む医薬組成物
TWI743059B (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
KR101561345B1 (ko) 제어방출되는 프로피온산 계열의 약제학적 조성물
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
JP5791817B2 (ja) 溶出性及び／又は吸収性が改善された経口投与用医薬組成物
JP6735007B2 (ja) エンタカポン含有医薬組成物
JP4603803B2 (ja) 放出制御医薬組成物およびこれを用いる製剤
EP3251669B1 (en) Solid composition of pyrrole carboxamide
CA3235787A1 (en) Methods of treating patients having type 1 diabetes with eflornithine
WO2023085300A1 (ja) 優れた溶出性を有する医薬組成物
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
BR112015018952B1 (pt) Composições farmacêuticas contendo dexcetoprofeno e tramadol, seu método de fabricação e seu uso
JP2019530755A (ja) セレコキシブを含む錠剤
HK1247826B (en) Solid composition of pyrrole carboxamide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: USMW, LLC

Free format text: FORMER OWNER(S): CANCER PREVENTION PHARMACEUTICALS, INC.

HB Alteration of name in register

Owner name: USWM, LLC

Free format text: FORMER NAME(S): USMW, LLC